

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Danske Bank A/S (“Notifier”). According to the notification, the total holdings in Optomed shares and votes held the by DanskeBank A/S is 5.08 per cent of all of the registered shares in Optomed on 26 September 2024.

The total number of the Company’s registered shares amounts to 19,630,397 shares. Each share entitles to one vote.

The total position of Notifier subject to the notification:

	% of shares and voting rights (total of A)	% of shares and voting rights through financial instruments (total of B)	Total of both in % (A+B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	5,08 %		5.08 %	19 630 397
Position of previous notification (if applicable)				

Notified details of the resulting situation on the date on which the threshold was crossed or reached:

A: Shares and voting rights

Class/type of shares ISIN code	Number of shares and voting rights		% of shares and voting rights	
	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI4000410881		997,607		5.08%
SUBTOTAL A		997,607		5.08 %

Information in relation to the person subject to the notification obligation as contained in the notification

The complete chain of controlled undertakings through which the shares, voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

Name	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both
Finnish Fund	5.07	-	5.07
Danica Pension Livsforsikringsaktie	0.01	-	0.01
	-	-	-

Further enquiries

Sakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye diseases, such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.

www.optomed.com